摘要
目的通过观察阿仑膦酸钠治疗绝经后骨质疏松或骨量减少1年后骨密度和骨吸收指标（β-CTX）的变化，了解骨密度变化与骨吸收指标变化的关系。方法入选了35例绝经后骨质疏松或骨量减少患者，给予阿仑膦酸钠70mg／w，碳酸钙600mg／d和维生素D125IU／d，治疗12m。在基线和治疗12in后进行DXA骨密度测定，在基线、治疗3m和12m后测定骨吸收指标β—CTX。结果治疗1年后腰椎2～4、股骨颈和全髋骨密度均有上升，而所有受试者治疗3m后β—CTX均较基线下降（74．21±43．66）％。治疗3m后β—CTX的变化率和治疗12m后腰椎2～4和股骨颈骨密度绝对值呈相关（Betastd=-0．418，P=0．017；Betastd=-0．321，p=0．032）。结论治疗3m骨吸收指标β-CTX的变化率有望成为预示患者对阿仑膦酸钠反应的早期指标。
Objective To investigate the association between the bone resorption marker and bone mineral density after one year alendronate treatment in postmenopausal Chinese women with osteoporosis or osteopenia. Methods 35 postmenopausal women with osteoporosis or osteopenia were included. All participants were treated with alendronate 70 mg per week, calcium 600 mg qd and Vitamin D 125 IU qd for 12 months. Bone mineral density （BMD） at lumbar spine 2 -4 （L2 -4） and hip sites were measured at baseline and after 12-month of treatment. The bone resorption marker 13-CTX was measured at baseline and after 3 and 12-month of treatment. Results After 12-month of treatment, the BMD at L2-4, femoral neck and total hip were increased significantly while the levels of β-CTX were decreased significantly. Compared with the baseline value,, the percent change of β-CTX after 3-month of treatment was （74.21±43.66） %. This 3-month percent change of β-CTX was associated with the absolute value of BMD at L2 - 4 and femoral neck after 12-monthof treatment （Betastd=-0.418, P=0.017 and Betastd=-0.321, P =0.032）. Conclusion The percent change of bone resorption marker Ⅱ- CTX after 3-month treatment is the potential early indicator to identify the responses of patients to alendronatetreatment.
出处
《老年医学与保健》
CAS
2015年第1期15-17,65,共4页
Geriatrics & Health Care
基金
国家自然科学基金(81270964,81200646)
上海市市级医院新兴前沿技术联合攻关项目(申康课题)(SHDC12013115)
上海市卫生系统优秀学科带头人培养计划(XBR2011014)
关键词
骨质疏松
骨转换指标
骨密度
Osteoporosis
Bone resorption marker
Bone mineral density
作者简介
通讯作者：汪纯，E—mail：chirs66@hotmail．com
